SK Bioscience (Korea) Performance
| 302440 Stock | 48,400 1,550 3.10% |
The entity owns a Beta (Systematic Risk) of -0.0505, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning SK Bioscience are expected to decrease at a much lower rate. During the bear market, SK Bioscience is likely to outperform the market. At this point, SK Bioscience has a negative expected return of -0.17%. Please make sure to validate SK Bioscience's market risk adjusted performance, coefficient of variation, jensen alpha, as well as the relationship between the mean deviation and standard deviation , to decide if SK Bioscience performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days SK Bioscience Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 25 B | |
| Total Cashflows From Investing Activities | -1.4 T |
302440 |
SK Bioscience Relative Risk vs. Return Landscape
If you would invest 5,460,000 in SK Bioscience Co on August 29, 2024 and sell it today you would lose (620,000) from holding SK Bioscience Co or give up 11.36% of portfolio value over 90 days. SK Bioscience Co is generating negative expected returns and assumes 2.5828% volatility on return distribution over the 90 days horizon. Simply put, 22% of stocks are less volatile than 302440, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
SK Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SK Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SK Bioscience Co, and traders can use it to determine the average amount a SK Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0663
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 302440 |
Estimated Market Risk
| 2.58 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average SK Bioscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SK Bioscience by adding SK Bioscience to a well-diversified portfolio.
SK Bioscience Fundamentals Growth
302440 Stock prices reflect investors' perceptions of the future prospects and financial health of SK Bioscience, and SK Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on 302440 Stock performance.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.36 % | |||
| Operating Margin | 0.47 % | |||
| Current Valuation | 5.52 T | |||
| Shares Outstanding | 76.78 M | |||
| Price To Book | 4.01 X | |||
| Price To Sales | 8.39 X | |||
| Revenue | 929 B | |||
| EBITDA | 493.33 B | |||
| Total Debt | 35.5 B | |||
| Cash Flow From Operations | 536.59 B | |||
| Earnings Per Share | 917.26 X | |||
| Total Asset | 2.11 T | |||
About SK Bioscience Performance
By analyzing SK Bioscience's fundamental ratios, stakeholders can gain valuable insights into SK Bioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if SK Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SK Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about SK Bioscience performance evaluation
Checking the ongoing alerts about SK Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SK Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SK Bioscience generated a negative expected return over the last 90 days | |
| About 69.0% of the company shares are owned by insiders or employees |
- Analyzing SK Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SK Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining SK Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SK Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of SK Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SK Bioscience's stock. These opinions can provide insight into SK Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for 302440 Stock analysis
When running SK Bioscience's price analysis, check to measure SK Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SK Bioscience is operating at the current time. Most of SK Bioscience's value examination focuses on studying past and present price action to predict the probability of SK Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SK Bioscience's price. Additionally, you may evaluate how the addition of SK Bioscience to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |